University Hospital - MU Healthcare
Welcome,         Profile    Billing    Logout  
 0 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Dandachi, Dima
PILLAR, NCT05374525: A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States

Completed
4
201
US
APRETUDE, Cabotegravir OLI
ViiV Healthcare
HIV Infections
08/24
08/24
ACCELERATE, NCT06374758: Accelerated ART Initiation for PWHIV Who Are Out of Care

Recruiting
4
120
US
The Accelerate model of care, bictegravir/emtricitabine/tenofovir alafenamide 50/200/25 mg
University of Missouri-Columbia, Gilead Sciences
HIV Infections, ART, Noncompliance, Patient
05/25
11/25
REPAVID-22, NCT05254990 / 2021-006951-32: Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

Terminated
3
409
Europe, US, RoW
Reparixin, Repertaxin L-lysine salt, Placebo, Matched placebo
Dompé Farmaceutici S.p.A
Infectious Pneumonia, Severe COVID-19
09/24
09/24
ICoN-1, NCT06418711: Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

Recruiting
3
234
US
Clofazimine Inhalation Suspension, MNKD-101, Placebo
Mannkind Corporation
MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
08/26
12/28
NCT05496868 / 2022-001612-25: Add-on Reparixin in Adult Patients With ARDS

Recruiting
2
66
Europe, US
Reparixin 600mg, REP, Matching Placebo, Control
Dompé Farmaceutici S.p.A, Dompè farmaceutici s.p.a.
Acute Respiratory Distress Syndrome, Adult
08/25
08/25
EMBRACE, NCT05996471: A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)

Active, not recruiting
2
128
US
VH3810109, Cabotegravir, Standard of care (SOC), rHuPH20
ViiV Healthcare
HIV Infections
11/24
05/26

Download Options